Immediate-Release APC Tablet Formulation With Minimal Excipients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of (R)-2-amino-3-phenylpropyl carbamate (APC) face challenges in providing immediate release for effective treatment of disorders due to difficulties in handling and swallowing solid medications, especially for patients with disease states that make swallowing difficult, and require rapid dissolution without high levels of excipients.
Innovation Solution
Development of immediate release compressed tablets containing 90-98% APC or its pharmaceutically acceptable salt, 1-5% binder, and 0.1-2% lubricant, which release at least 85% of the active ingredient within 15 minutes, maintaining consistent dissolution rates across different pH levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If high levels of excipients are used in APC formulations, then the tablet can be easier to swallow and handle, but the dissolution rate and immediate release performance deteriorates
Solution Approach 1:
The patent changes the concentration parameters of excipients to achieve immediate release. Specifically, it uses binders at 1-5% weight and lubricants at 0.1-2% weight, which are lower than conventional formulations. This parameter optimization allows the tablet to dissolve rapidly (85% within 15 minutes) while still maintaining acceptable swallowability through the use of highly soluble excipients like mannitol and aspartame.
2Speed
If the tablet contains 90-98% APC with minimal excipients, then the dissolution rate improves, but the tablet may be more difficult to handle and swallow
Solution Approach 1:
The patent optimizes the parameters of the minimal excipients used. It selects highly water-soluble binders (like hydroxypropyl cellulose at 1-5%) and lubricants (like magnesium stearate at 0.1-2%), and includes sweeteners (aspartame 1-5%, mannitol 1-5%) to improve sensory properties. These parameter selections ensure that even with 90-98% APC content, the tablet remains palatable and easier to swallow.
Solution Approach 2:
The patent creates a composite tablet formulation combining APC with a specific mixture of excipients including binders, lubricants, sweeteners, and colorants. This composite approach allows the tablet to achieve immediate release performance while compensating for the reduced excipient content through synergistic combinations of materials that improve both dissolution and patient acceptability.
3Reliability
If the formulation is optimized for immediate release with 85% release within 15 minutes, then the therapeutic effectiveness improves, but the formulation complexity increases
Solution Approach 1:
The patent achieves immediate release (85% within 15 minutes) by changing the parameters of excipient selection and concentration. It uses highly soluble binders like hydroxypropyl cellulose at optimized levels (1-5%), minimal lubricants (0.1-2%), and incorporates solubility-enhancing agents. These parameter changes create a straightforward compressed tablet formulation without requiring complex delivery mechanisms, maintaining manufacturing simplicity while achieving reliable therapeutic effectiveness.
Data Source
AI summary
The present invention relates to solid pharmaceutical formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.